Semaglutide Cardiovascular Data East Asian

## Semaglutide in East Asian Populations: Long-Term Cardiovascular Benefit and Safety ### Clinical Evidence & Efficacy **Cardiovascular Outcomes in East Asian Subgroups** The available evidence for semaglutide's cardiovascular effects in East Asian populations is derived primarily from subgroup analyses of global trials and dedicated Asian studies, rather than large-scale East Asian-specific CVOTs. | Study/Trial | Population | Key Cardiovascular Findings | Evidence Level | |-------------|------------|---------------------------|----------------| | **SELECT trial** (subcutaneous semaglutide 2.4 mg) | 17,604 patients with ASCVD + obesity/overweight (BMI ≥27 kg/m²), no diabetes; ~10% Asian enrollment | MACE reduction: HR 0.80 (95% CI: 0.72–0.90, p<0.001); CV death: HR 0.85 (95% CI: 0.71–1.01, NS); CV death/HF composite: HR 0.82 (95% CI: 0.71–0.96) | Level A (global trial with Asian subgroup) | | **SOUL trial** (oral semaglutide 14 mg) | 9,650 participants with T2D + ASCVD/CKD; Asian enrollment included | MACE reduction: HR 0.86 (95% CI: 0.77–0.96, p=0.006); incidence 12.0% vs 13.8% placebo | Level A (global trial with Asian subgroup) | | **FLOW trial** (subcutaneous semaglutide 1.0 mg) | T2D + CKD across KDIGO risk categories | MACE reduction: HR 0.82 (95% CI: 0.68–0.98, p=0.03); all-cause mortality: HR 0.80 (95% CI: 0.67–0.95, p=0.01) | Level A (global trial) | | **STEP 11 trial** (subcutaneous semaglutide 2.4 mg) | Asian adults (n=201), BMI ≥25 kg/m² with ≥1 comorbidity or BMI ≥35 kg/m² | Weight loss: −14.3% vs −1.3% placebo (p<0.001); cardiometabolic risk factors improved commensurately | Level B (dedicated Asian trial, limited sample size) | **Key Observations for East Asian Populations:** - **Subgroup consistency**: Subanalyses of Asian patients in global trials (SELECT, SOUL, STEP 1) demonstrated efficacy and safety comparable to the total study population [8]. The AHA Scientific Statement notes that efficacy and safety in Asian patients were comparable to the total study population evaluated in many trials [8]. - **Cardiovascular mortality**: In SELECT, the CV death endpoint (HR 0.85; 95% CI: 0.71–1.01) did not meet the required significance threshold in hierarchical testing [1][2]. - **Renal-cardiovascular protection**: FLOW trial demonstrated consistent MACE reduction across CKD stages (all P-interaction ≥0.13), with pronounced mortality benefit in patients with UACR ≥300 mg/g (HR 0.70; 95% CI: 0.57–0.85) [5]. ### Safety Profile **Adverse Events in Asian Populations** | Safety Parameter | Semaglutide | Placebo | Notes | |-----------------|-------------|---------|-------| | **Any AE** (STEP 11) | 89% | 78% | Consistent with GLP-1 RA class profile | | **GI AEs** (STEP 11) | Most common (nausea, vomiting, diarrhea) | Lower incidence | Expected class effect | | **Serious AEs** (STEP 11) | 13% | 8% | Specific nature not detailed in summary | | **GI disorders** (SOUL) | 5.0% | 4.4% | Oral formulation | | **Discontinuation due to AEs** (OASIS 2) | 4.5% | — | Low discontinuation rate | | **Serious AEs** (SOUL) | 47.9% | 50.3% | Comparable between groups | **Safety Considerations Specific to East Asian Populations:** - **GI tolerability**: Gastrointestinal adverse events (nausea, diarrhea, vomiting) were more frequent with semaglutide (63.4% in OASIS 2) versus placebo (34.8%), consistent with the GLP-1 RA class profile [3]. - **Low discontinuation**: Despite higher GI AE rates, few participants discontinued treatment due to adverse events (4.5% in OASIS 2) [3]. - **No unexpected safety signals**: The STEP 11 trial reported no unexpected safety signals in Asian adults [4]. - **Hypoglycemia risk**: GLP-1 RAs are insulin-independent and associated with low hypoglycemia risk, which is particularly relevant for Asian populations where hypoglycemia is a common concern [8]. ### Guideline Recommendations | Guideline | Recommendation | Class/Level | |-----------|---------------|-------------| | **iCARDIO Alliance 2025** | Semaglutide 2.4 mg weekly for obesity management with ASCVD risk reduction | Guideline-recommended | | **Chinese Hypertension Guidelines** | Semaglutide recommended for overweight/obese patients with hypertension, based on SELECT trial evidence | Guideline-recommended | | **AHA Scientific Statement (Asian Americans)** | GLP-1 RAs encouraged as therapeutic choice; efficacy/safety in Asian patients comparable to total population | Scientific statement | ### Critical Gaps in Evidence 1. **No dedicated East Asian CVOT**: Large-scale cardiovascular outcomes trials specifically powered for East Asian populations are lacking. Current evidence relies on subgroup analyses of global trials [8]. 2. **Limited disaggregated data**: The AHA Scientific Statement specifically notes "limited data for AsA disaggregated subgroups" [8]. 3. **Short-term follow-up in Asian-specific trials**: The STEP 11 trial (68 weeks) and OASIS 2 (68 weeks) have relatively short follow-up durations for cardiovascular endpoint assessment [3][4]. 4. **Gender imbalance**: STEP 11 had 74% female participants, potentially limiting generalizability to males [4]. 5. **Small sample sizes**: Asian-specific trials (STEP 11: n=201; OASIS 2: n=201) are underpowered for cardiovascular event detection [3][4]. ### Conclusion Available evidence from global trial subgroup analyses and dedicated Asian studies supports comparable cardiovascular benefit and safety of semaglutide in East Asian populations to the overall trial populations, with MACE reduction of approximately 14–20% and a safety profile consistent with the GLP-1 RA class. However, the absence of large-scale, East Asian-specific CVOTs with long-term follow-up represents a significant evidence gap that warrants further investigation. --- *This analysis is based on retrieved evidence from clinical trials, guidelines, and scientific statements. Clinical decision-making should consider individual patient characteristics and local regulatory approvals. The evidence for East Asian populations is derived primarily from subgroup analyses and smaller dedicated studies, which may have limited generalizability.*